In contrast, Allo15CAR33-NKT cells demonstrated cytotoxicity against both CD33+ and CD33- AML tumor cells (Fig. 3e and Supplementary Fig. 7a), indicating they can target tumor cells through both CAR33-dependent and independent mechanisms. This evidence concerns the gene CD33 and acute myeloid leukemia.